NCT03751839 (BOLD-1) is a NA clinical trial of Biochemical Tests in Type 1 Diabetes Mellitus, sponsored by Christian Meier.

Who is sponsoring NCT03751839?

NCT03751839 is sponsored by Christian Meier.

What drugs are being tested in NCT03751839?

Interventions in NCT03751839: Biochemical Tests, Osteodensitometry, Clinical Tests, HR-QCT, HR-pQCT.

What condition does NCT03751839 study?

NCT03751839 studies Type 1 Diabetes Mellitus.

Is NCT03751839 still recruiting?

NCT03751839 is currently completed. Last updated 27 July 2021.

Last reviewed 2021-07-27 · How we verify

NCT03751839: BOLD-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Microarchitecture, Bone Strength and Fracture Risk in Long-term Type 1 Diabetes

Completed NA Last updated 27 July 2021

What this trial tests

NA trial testing Biochemical Tests in Type 1 Diabetes Mellitus in 136 participants. Completed in 1 July 2021.

Timeline

1 October 2018

Primary endpoint
1 July 2021

1 July 2021

Quick facts

Lead sponsor	Christian Meier
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	136
Start date	1 October 2018
Primary completion	1 July 2021
Estimated completion	1 July 2021
Sites	1 location across Switzerland

Drugs / interventions tested

Biochemical Tests
Osteodensitometry
Clinical Tests
HR-QCT
HR-pQCT

Conditions studied

Type 1 Diabetes Mellitus — all drugs for Type 1 Diabetes Mellitus →

Sponsor

Christian Meier

Who can join

Adults 40 to 80, any sex, with Type 1 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This single center case control study will assess differences in bone structure between women and men with longstanding type 1 diabetes (diabetes duration\>/= 25 years) and healthy controls.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Type 1 Diabetes Mellitus

Currently open trials in the same condition.

NCT07142252 — Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus · Phase 2 · recruiting
NCT07296276 — Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM · NA · recruiting
NCT07409701 — Gamification Intervertion in Children With Type 1 Diabetes · NA · recruiting
NCT07356089 — Twiist Postmarket Surveillance Study for Type 1 Diabetes · recruiting
NCT07434154 — Evaluation of Oxidative Stress: Comparison Between Type 1 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03751839 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Christian Meier
Last refreshed: 27 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03751839.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing